These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1705762)

  • 21. [Corticostesteroids in the treatment of scleroderma].
    Szczepański A
    Przegl Dermatol; 1971; 58(6):749-53. PubMed ID: 5139315
    [No Abstract]   [Full Text] [Related]  

  • 22. [Piascledine in the treatment of scleroderma].
    Szczepański A; Dabrowska H; Moskalewska K
    Przegl Dermatol; 1974; 61(4):525-7. PubMed ID: 4849404
    [No Abstract]   [Full Text] [Related]  

  • 23. [Low-molecular dextran (40,000) in the treatment of scleroderma].
    Szczepański A; Zielińska Z; Polkowska M; Lorenc B
    Przegl Dermatol; 1975; 62(1):79-82. PubMed ID: 1111035
    [No Abstract]   [Full Text] [Related]  

  • 24. [Scleroderma and esophageal changes: treatment and instrumental control].
    Altomare GF; Allara A; Pigatto PD
    G Ital Dermatol Venereol; 1984; 119(4):263-6. PubMed ID: 6490099
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic effectiveness of ultrasonics and lidase phonophoresis in various forms of scleroderma].
    Didenko IG
    Vestn Dermatol Venerol; 1978 Jun; (6):76-9. PubMed ID: 354249
    [No Abstract]   [Full Text] [Related]  

  • 26. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
    Faggioli P; Giani L; Mazzone A
    Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
    [No Abstract]   [Full Text] [Related]  

  • 27. Salazopyrin in the treatment of scleroderma.
    Stáva Z; Kobíková M
    Br J Dermatol; 1977 May; 96(5):541-4. PubMed ID: 17429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimethyl sulfoxide in the treatment of scleroderma.
    Engel MF
    South Med J; 1972 Jan; 65(1):71-3. PubMed ID: 5058095
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of piascledine treatment of scleroderma].
    Szczepański A; Dabrowska H; Moskalewska K
    Przegl Dermatol; 1975; 62(4):555-8. PubMed ID: 1162105
    [No Abstract]   [Full Text] [Related]  

  • 30. Salazopyrin (azulfidine) treatment in scleroderma.
    Dover N
    Isr J Med Sci; 1971 Nov; 7(11):1301-3. PubMed ID: 4400695
    [No Abstract]   [Full Text] [Related]  

  • 31. Cyclosporin in localized and systemic scleroderma--a clinical study.
    Wörle B; Hein R; Krieg T; Meurer M
    Dermatologica; 1990; 181(3):215-20. PubMed ID: 2269381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of scleroderma with depolymerizing agents].
    Konopík J; Krs V
    Cas Lek Cesk; 1982 Nov; 121(44):1368-72. PubMed ID: 7172189
    [No Abstract]   [Full Text] [Related]  

  • 33. Stimulating circulation to end stasis in scleroderma.
    Yuan X; Li JD; Chen WJ; Li ZS; Zhu HT; Liu JW; Zhu MJ
    Chin Med J (Engl); 1981 Feb; 94(2):85-93. PubMed ID: 6786844
    [No Abstract]   [Full Text] [Related]  

  • 34. [Studies on the solubility of skin collagen in scleroderma and the effect of D-penicillamine].
    Zimmermann BK; Balda BR
    Arch Dermatol Forsch; 1972; 243(4):357-63. PubMed ID: 5079382
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.
    Caramaschi P; Biasi D; Ferrari M; Volpe A; Martinelli N; Carletto A; Dal Forno P; Bambara LM
    Rheumatol Int; 2005 May; 25(4):250-4. PubMed ID: 14963694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systemic sclerosis (scleroderma) without scleroderma].
    Nadashkevych ON
    Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Observations of the course of scleroderma after combined Hylase-carnitine therapy].
    Nitzschner H
    Z Arztl Fortbild (Jena); 1975 Nov; 69(21):1108. PubMed ID: 1226844
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of pentoxifylline in the treatment of systemic sclerosis and lipodermatosclerosis: a unifying hypothesis?
    Goldman MP
    J Am Acad Dermatol; 1994 Jul; 31(1):135-6. PubMed ID: 8054069
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of scleroderma].
    Wüthrich B
    Schweiz Rundsch Med Prax; 1973 Sep; 62(38):1149-55. PubMed ID: 4148265
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.